An FDA panel is meeting to determine if compounding pharmacies should be permitted to produce seven popular injectable peptides currently lacking large-scale clinical approval.
Key facts
- •The FDA committee is reviewing seven compounds, including TB-500, BPC-157, and MOTs-C, which are marketed for uses like injury recovery and weight loss.
- •FDA career scientists advise against approving the compounds for compounding, noting that data is primarily limited to animal studies.
- •Health Secretary Robert F. Kennedy Jr. has publicly supported lifting restrictions on peptide therapies.
- •The FDA recently added several members to the advisory committee with professional ties to the peptide industry and compounding pharmacies.
- •If reclassified, clinicians could potentially prescribe these peptides for conditions beyond the specific indications currently under review.
The Food and Drug Administration is convening the Pharmacy Compounding Advisory Committee for a two-day meeting starting Thursday to evaluate whether compounding pharmacies should be authorized to manufacture seven popular injectable peptides. The compounds under review, which include TB-500, BPC-157, and MOTs-C, have not undergone the large-scale clinical trials typically required for FDA drug approval. The meeting is scheduled to conclude on Friday afternoon.
Safety Concerns and Regulatory Debate
FDA career scientists have recommended against allowing compounding pharmacies to produce these peptides, citing a lack of human clinical evidence and reliance on preclinical animal studies. In a pre-meeting review, the agency noted that evidence for compounds like Semax does not establish effectiveness. Critics, including cell biologist Paul Knoepfler, warn that these substances carry risks, such as potential immune responses or the promotion of cancer growth, if administered at incorrect doses. Conversely, industry proponents argue that current restrictions have pushed demand into an unregulated grey market of overseas suppliers. During a briefing by the American Academy of Peptide Medicine, podcaster Gary Brecka stated that demand for peptides persists regardless of regulatory status. Supporters, including Dr. Anant Vinjamoori of Hims & Hers, argue that years of clinical experience across thousands of physicians suggest the therapies can be beneficial.
Political and Administrative Context
The upcoming review occurs amid broader tensions regarding the 'Make America Healthy Again' agenda supported by Health Secretary Robert F. Kennedy Jr., who has advocated for lifting restrictions on peptides. In June, the FDA overhauled its advisory committee, appointing several members with ties to the peptide industry or compounding clinics. On Tuesday, the agency added further temporary voting members from academic institutions to provide expertise on specific compounds. FDA officials did not respond to inquiries regarding these committee changes.
Timeline
- JuneThe FDA overhauled the roster for the Pharmacy Compounding Advisory Committee.
- TuesdayThe FDA added temporary voting members to the advisory committee.
- ThursdayThe two-day advisory committee meeting is scheduled to begin.
Advertisement
This article was independently rewritten by ManyPress editorial AI from reporting originally published by NPR Health.
